Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.A live webcast of the Company's prese ...

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology.The peer-reviewed article reports results from a randomized, double-blind, placebo-cont ...

Core Viewpoint - Cardiol Therapeutics Inc. has successfully completed a private placement of units, raising a total of $14.85 million to support its research and clinical development programs for heart disease therapies [1][3]. Financing Details - The company issued 11,423,078 units at a price of $1.30 per unit, which includes the full exercise of the over-allotment option by the underwriter [1]. - Each unit consists of one Class A common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2]. - The underwriter received a cash commission of 6% of the aggregate gross proceeds from the offering [2]. Use of Proceeds - The net proceeds from the financing will be utilized to advance research and clinical development programs, as well as for general administrative expenses and working capital [3]. Regulatory Compliance - The offering was conducted as a private placement under National Instrument 45-106, allowing sales to qualified investors in Canada, excluding Quebec [4]. - The units issued are not subject to resale restrictions in Canada under applicable securities laws [4]. Company Overview - Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting inflammation and fibrosis associated with heart conditions [6]. - The company is conducting the MAVERIC Program to evaluate CardiolRx™ for recurrent pericarditis and has received Orphan Drug Designation from the U.S. FDA for this treatment [7]. - Additionally, the ARCHER Program is studying CardiolRx™ for acute myocarditis, a significant cause of heart failure in young adults [8]. - Cardiol is also developing CRD-38, a novel subcutaneous drug formulation for inflammatory heart disease, addressing a major healthcare cost issue in the U.S. [9].

Core Viewpoint - Cardiol Therapeutics Inc. has announced a private placement offering to raise gross proceeds of $13.5 million by selling 10,384,616 units at a price of $1.30 per unit, with an option for the underwriter to purchase an additional 10% of the units sold [1][4]. Group 1: Offering Details - The offering consists of units that include one Class A common share and one-half of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2]. - The offering is scheduled to close on or about January 23, 2026, subject to necessary approvals, including TSX approval, and the negotiation of an underwriting agreement [4]. - A cash commission of 6% of the aggregate gross proceeds will be paid to the underwriter upon closing of the offering [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance the company's research and clinical development programs, as well as for general and administrative expenses and working capital [3]. Group 3: Company Overview - Cardiol Therapeutics is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting conditions like pericarditis and myocarditis [9][10]. - The company is also developing CRD-38, a novel drug formulation for treating inflammatory heart disease, which is a significant cause of death and hospitalization in developed countries [12].

Core Viewpoint - Cardiol Therapeutics Inc. has announced a private placement offering to raise gross proceeds of $13.5 million by selling 10,384,616 units at a price of $1.30 per unit, with an option for the underwriter to purchase an additional 10% of the units sold [1][4] Group 1: Offering Details - The offering consists of units that include one Class A common share and one-half of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2] - The offering is scheduled to close on or about January 23, 2026, subject to necessary approvals, including from the TSX [4] - A cash commission of 6% of the aggregate gross proceeds will be paid to the underwriter upon closing [4] Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance research and clinical development programs, as well as for general administrative expenses and working capital [3] Group 3: Company Overview - Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting conditions like pericarditis and myocarditis [9][10] - The company is also developing CRD-38, a novel drug formulation for inflammatory heart disease, which is a significant cause of death and hospitalization in developed countries [12]

Core Insights - Cardiol Therapeutics Inc. has surpassed 50% patient enrollment in its Phase III MAVERIC trial, which evaluates CardiolRx™ for preventing disease recurrence in patients with recurrent pericarditis [1][2][3] Company Overview - Cardiol Therapeutics is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™ [5][9] - The company aims to address the high unmet medical need in recurrent pericarditis, a condition that significantly impacts patients' quality of life [7] Clinical Trial Progress - The MAVERIC trial is designed to enroll approximately 110 patients across 25 leading cardiovascular research centers in the U.S., Canada, and Europe, with full enrollment expected by Q2 2026 [4][6] - The primary endpoint of the trial is freedom from new episodes of recurrent pericarditis after six months of treatment, with secondary endpoints including pain scores and inflammatory biomarker changes [4] Scientific Rationale and Market Potential - Data from the Phase II MAvERIC-Pilot study showed that CardiolRx™ led to rapid and sustained reductions in pericarditis pain and inflammation, supporting its advancement to Phase III [3][4] - The company believes that CardiolRx™'s oral, non-immunosuppressive profile positions it as a more accessible treatment option compared to biologic therapies, which are projected to generate over $800 million in U.S. revenues in 2026 [3][4]

Core Insights - Cardiol Therapeutics Inc. announced significant findings from the Phase II ARCHER trial, demonstrating that CardiolRx™ improves heart structure in patients with acute myocarditis, supporting its potential for broader applications in inflammatory cardiac conditions [2][4][5] Group 1: Trial Results - The ARCHER trial showed a significant reduction in left ventricular (LV) mass by 9.2 grams (from 130.3g in placebo to 121.1g in the active group, p=0.0117), indicating meaningful structural recovery [3][8] - Extracellular volume (ECV) decreased by 3.7 mL (from 37.3mL in placebo to 33.6mL in the active group, p=0.0538), and intracellular volume (ICV) reduced by 5.6 mL (from 91.2mL in placebo to 85.6mL in the active group, p=0.0928) [8][9] - Left atrial end systolic volume (LAESV) was reduced by 8.1 mL (p=0.0376) and left ventricular end diastolic volume (LVEDV) decreased by 7.4 mL (p=0.0981), reflecting improved heart function [8][9] Group 2: Clinical Implications - The results provide clinical evidence that CardiolRx™ can reduce inflammation-driven structural damage in the heart, a key factor in heart failure progression [4][5] - The findings support the scientific rationale for Cardiol's lead Phase III program in recurrent pericarditis and indicate potential for development across various inflammatory cardiac conditions [4][5][17] Group 3: Company Overview - Cardiol Therapeutics is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with CardiolRx™ as its lead candidate [15][18] - The company is also advancing CRD-38, a next-generation small molecule targeting chronic inflammatory heart conditions [18]

Core Insights - Cardiol Therapeutics has received a Notice of Allowance for a U.S. patent that will protect its heart drugs until late 2040, specifically for CardiolRx™ and CRD-38 in treating various cardiac conditions [2][3][5] Intellectual Property Protection - The new patent will provide broad intellectual property protection for Cardiol's therapies against a range of heart diseases, including heart failure, myocarditis, and atherosclerosis [2][5] - This patent allowance enhances Cardiol's market position and intellectual property portfolio, complementing its existing U.S. Orphan Drug Designation for pericarditis [3][5] Clinical Development Programs - Cardiol is advancing late-stage clinical programs for recurrent pericarditis and acute myocarditis, addressing significant unmet medical needs [3][9] - The company is preparing to initiate first-in-human clinical evaluations of CRD-38, a novel therapy for inflammatory heart disease, including heart failure [3][9] Upcoming Presentations and Trials - Cardiol plans to present comprehensive data from the ARCHER trial, a Phase II study of CardiolRx™ in acute myocarditis, at the European Society of Cardiology Annual Meeting on November 29 [3][8] - An update on the pivotal Phase III MAVERIC trial in recurrent pericarditis will also be provided as patient enrollment accelerates [3][7]

Core Insights - Cardiol Therapeutics is set to present full data from its Phase II ARCHER trial at the European Society of Cardiology meeting, focusing on the effects of CardiolRx™ in patients with acute myocarditis [2][5] - The trial demonstrated significant improvements in cardiac structure, including a notable reduction in left ventricular mass, indicating the potential of CardiolRx™ as an effective anti-inflammatory treatment for heart disease [3][4][6] Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company specializing in late-stage anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™ [8] - The company is also developing CRD-38, a novel subcutaneously administered formulation aimed at treating heart failure, which is a leading cause of death and hospitalization globally [11] Trial Details - The ARCHER trial enrolled 109 patients from various countries, including the United States, France, Brazil, and Israel, to assess the safety and efficacy of CardiolRx™ in acute myocarditis [6] - The trial's design and rationale were previously published, emphasizing the importance of addressing inflammation in cardiac conditions [6] Upcoming Events - A webcast conference call is scheduled for December 1, 2025, to discuss the ARCHER trial findings and their implications for Cardiol's future programs in inflammatory heart disease [7]

Core Insights - Cardiol Therapeutics Inc. has successfully completed a private placement offering, raising US$11.4 million to support its operations and development of heart disease therapies [3][4]. Financing Details - The company sold a total of 11.4 million units at a price of US$1.00 per unit, with each unit consisting of one common share and one-half of a common share purchase warrant [4]. - The warrants allow holders to acquire additional common shares at an exercise price of US$1.35 for 24 months, with an acceleration provision if the share price exceeds US$2.00 for five consecutive trading days [4]. Clinical Development - The funds will support the ongoing pivotal Phase III MAVERIC trial for CardiolRx™, which targets recurrent pericarditis, and the development of the next-generation CRD-38 formulation for heart failure [6][10]. - Recent findings from the ARCHER trial indicate a significant reduction in left ventricular (LV) mass, providing clinical validation for Cardiol's therapies in inflammatory heart disease [4][12]. Market Potential - The company aims to address a significant unmet need in heart failure, where five-year mortality rates exceed 50%, and healthcare costs in the U.S. related to heart failure exceed US$30 billion annually [4][12].